miRNA Sequencing and Assay Companies and Market Forecast
The global miRNA sequencing and assay market size is calculated at US$ 391.73 in 2024, grew to US$ 443.95 million in 2025, and is projected to reach around US$ 1369.11 million by 2034. The market is expanding at a CAGR of 13.33% between 2024 and 2034.
Top Companies in the miRNA Sequencing and Assay Market are:
- Thermo Fisher Scientific, Inc.
- Illumina, Inc.
- QIAGEN
- PerkinElmer, Inc.
- Abcam plc
- New England Biolabs
- Takara Bio Inc.
- Lexogen GmbH
- Norgen Biotek Corp.
- Maravai LifeSciences
- HTG Molecular Diagnostics, Inc.
- Meridian Bioscience, Inc.
- System Biosciences, LLC
International Trade Data for Activated Carbon and Similar Preparations
| CONSIGNEE_NAME | SHIPPER_NAME | LOADING_PORT | SUMOFQUANTITY | SUMOFWEIGHT |
| EUCATEX OF NORTH AMERICA INC | EUCATEX INDUSTRIA E COMERCIO LTDA | 35177, SAO PAULO | 901730 | 5319866664 |
| PEREZ TRADE COMPANY | SYLVAMO EXPORT LTDA | 30107, CARTAGENA | 113014 | 3696665 |
| NATIONAL PRESTO IND INC | LEERAY ENTERPRISES LIMITED | 57078, YANTIAN | 35314 | 148924 |
| EUCATEX OF NORTH AMERICA INC | EUCATEX INDUSTRIA E COMERCIO LTDA | 35177, SAO PAULO | 23800 | 281520 |
| NATIONAL PRESTO IND INC | LEERAY ENTERPRISES LIMITED | 57078, YANTIAN | 20141 | 75800 |
| PEREZ TRADE COMPANY | SYLVAMO EXPORT LTDA | 35177, SAO PAULO | 17528 | 1089922 |
| EUCATEX OF NORTH AMERICA INC | EUCATEX INDUSTRIA E COMERCIO LTDA | 35177, SAO PAULO | 16000 | 148102 |
| NATIONAL PRESTO IND INC | LEERAY ENTERPRISES LIMITED | 57078, YANTIAN | 15505 | 57422 |
| EUCATEX OF NORTH AMERICA INC | EUCATEX INDUSTRIA E COMERCIO LTDA | 30107, CARTAGENA | 15200 | 227661 |
| SHAW INDUSTRIES GROUP | JIANGSU KENTIER WOOD CO LIMITED | 57020, NINGPO | 13440 | 625268 |
Latest Announcements by Industry Leaders
In March 2024, since its start in the 1970s, genetic sequencing has advanced significantly, according to Dr. Kuo, the CEO of the business. One of the most intriguing new advances in biotechnology is long-read RNA sequencing, which is driving the industry to move away from short-read sequencing. We think that a fresh generation of biotechnology advances might be accelerated by our solution. Its potential is demonstrated by the support of some of the top life science investors in the UK. The money will support our efforts to uncover the hidden realm of RNA and open up fascinating new uses.
Recent Developments in the miRNA Sequencing and Assay Market
- In October 2024, Sanofi made a strategic equity investment in Resalis Therapeutics to expedite RES-010's clinical trial progress. Resalis Therapeutics is positioned as a prospective participant in the RNA therapeutics market due to its emphasis on miRNA-based medicines. The business is well-positioned to significantly advance the treatment of metabolic illnesses because of its creative strategy and the increasing backing of important industry partners.
- In October 2024, American scientists Victor Ambros and Gary Ruvkun were named the 2024 Nobel Prize laureates in Physiology or Medicine for their research on microRNA. Their findings provide insight into the origins of sophisticated life on Earth and the diverse range of tissues that make up the human body.
If you have any questions, please feel free to contact us at sales@towardshealthcare.com
Keypoints
- Company Overview
- Locations Subsidiaries/Geographic reach
- Key Executives
- Company Financials
- Patents registered
- SWOT Analysis
- Applications Catered
- Strategic collaborations
- Recent Developments
- Competitive Benchmarking